Inhibitors of type-I interleukin-1 receptor from microbial metabolites

Journal of Antibiotics

Volumn 50, Issue 6, 1997, Pages 484-489

  Stefanelli, Stefania ^a   Corti, Emiliana ^a   Montanini, Nicoletta ^a   Denaro, Maurizio ^a,b   Sarubbi, Edoardo ^a,c  

^a Gruppo Lepetit SpA   (Italy)

^b AMYLIN PHARMACEUTICALS INC   (United States)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIFLAVINE; ANTIFUNGAL AGENT; AZALOMYCIN F; GUANIDINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NIPHIMYCIN; SCOPAFUNGIN; UNCLASSIFIED DRUG;

ARTICLE; ASPERGILLUS; BIOSYNTHESIS; DRUG SYNTHESIS; FERMENTATION; PRIORITY JOURNAL; STREPTOMYCES; STRUCTURE ACTIVITY RELATION;

EID: 0030875624     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.7164/antibiotics.50.484     Document Type: Article

References (15)

1. DINARELLO, C. A.: Interleukin-1. Adv. Pharmacol. 25: 21-51, 1994
2. DOWER, K. S.; W. FANSLOW, C. JACOBS, S. WAUGH, J. E., SIMS & M. B. WIDMER: Interleukin-1 antagonists. Therap. Immunol. 1: 113-122, 1994
3. SARUBBI, E.; S. D. YANOFSKY, R. W. BARRETT & M. DENARO: A cell-free,nonisotopic, high throughput assay for inhibitors of type-I interleukin-1 receptor. Anal. Biochem. 237: 70-75, 1996
4. WHITEHORN, E.; E. TATE, S. D. YANOFSKY, L. KOCHERSPERGER, A. DAVIS, R. B. MORTENSEN, S. YONKOVICH, K. BELL, W. J. DOWER & R. W. BARRETT: A generic method for expression and use of "tagged" soluble versions of cell surface receptors. Bio/technology 13: 1215-1219, 1995
5. SARUBBI, E.: Particle concentration fluorescence as an alternative to radioactivity for cytokine receptor binding assays. J. Immunol. Methods 198: 113-118, 1996
6. HERTZBERG, R. P.; R. K. JOHNSON, M. J. CARANFA, C. C. MYERS, L. MACKENZIE, A. BREEN, T. A. TOMASZEK Jr, T. D. MEEK, C. DEBOUCK, S. H. MAI, J. S. CULP & T. A. FRANCIS: Mechanism-based strategies for the discovery of natural product inhibitors of HIV. In New drugs from natural sources. Ed., J. D. COOMBES, pp. 46-58, IBC Technical Services Ltd., 1992
7. BASSI, L.; B. JOOS, P. GASSMANN, H. P. KAISER, H. LEUENBERGER & W. KELLER-SCHIERLEIN: On the structure elucidation of niphimycin, Part I. Purification and characterization of the niphimycins Iα and Iβ; degradation by nitric acid. Helv. Chim. Acta 66: 92-108, 1983
8. ARAI, M.: Azalomycin B and F, two new antibiotics.II. Properties of azalomycins B and F. J. Antibiotics Ser. A, 13: 51-56, 1960
9. RAISTRICK, H. & P. RUDMAN: Biochemistry of microorganisms- XCVII. Flavipin, a crystalline metabolite of Aspergillus flavipes and Aspergillus terreus. Biochem. J. 63: 395-406, 1956
10. MCFARTHING, K. G.: Selection and synthesis of receptor-specific radioligands. In Receptor-ligand interactions: a practical approach. Ed., E.C. HULME, pp. 1-18, Oxford University Press, New York, 1992
11. LABORDE, A. L.; J. A. SHELLY, S. E. TRUESDELL, V. P. MARSHALL, J. I. CIALDELLA, W. F. LIGGETT, D. A. YUREK, D. G. CHIRBY, J. W. PASLAY, C. K. MARSCHKE & M. S. KUO: High-volume screening of natural products for IL-1 receptor level antagonists. Develop. Ind. Microb. 32: 285-296, 1993
12. AURON, P. E.; G. J. QUIGLEY, L. J. ROSENWASSER & L. GEHRKE: Multiple aminoacid substitutions suggest a structural basis for the separation of ological activity and receptor binding in a mutant interleukin-1 protein. Biochemistry 31: 6632-6638, 1992
13. LABRIOLA-TOMPKINS, E.; C. CHANDRAN, K. L. KAFFKA, D. BIONDI, B. J. GRAVES, M. HATADA, V. S. MADISON, J. KARAS, P. L. KILIAN & G. JU: Identification of the discontinuous binding site in human interleukin 1β for the type I interleukin 1 receptor. Proc. Natl. Acad. Sci. USA 88: 11182-11186, 1991
14. EVANS, R. J.; J. BRAY, J. D. CHILDS, G. P. A. VIGERS, B. J. BRANDHUBER, J. J. SKALICKY, R. C. THOMPSON & S. P. EISENBERG: Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and IL-1β by site-directed mutagenesis. J. Biol. Chem. 270: 11477-11483, 1995
15. STRASSMANN, G.; F. D'ALESSANDRO, M. FONG, R. P. NORDAN, P. NICKEL & R. CHIZZONITE: Suramin blocks the binding of interleukin-1 to its receptor and neutralizes IL-1 biological activities. Int. J. Immunopharm. 16: 931-939, 1994